Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
作者： Michael Hallek
DOI: 10.1182/ASHEDUCATION-2013.1.138
关键词: Leukemia 、 Alemtuzumab 、 Internal medicine 、 Fludarabine 、 Bendamustine 、 Chronic lymphocytic leukemia 、 Oncology 、 Ibrutinib 、 Rituximab 、 Ofatumumab 、 Medicine 、 Immunology
摘要: The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes. Several new drugs have been approved for CLL treatment (fludarabine, bendamustine, and the monoclonal antibodies alemtuzumab, rituximab, ofatumumab) many more are in advanced clinical development to be this disease. In addition, extreme heterogeneity course our improved ability foresee prognosis by use clinical, biological, genetic parameters now allow us characterize patients with a very mild onset course, an intermediate prognosis, or aggressive high-risk leukemia. Therefore, it becomes increasingly challenging select right strategy each condition. This article summarizes currently available diagnostic therapeutic tools gives integrated recommendation how manage 2013. Moreover, I propose we might integrate novel agents therapy into sequential approaches near future.
ashpublications.org
hematologylibrary.org参考文章(101)
Peter Hillmen, John G. Gribben, George A. Follows, Donald Milligan, Hazem A. Sayala, Paul Moreton, David G. Oscier, Claire E. Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Nathwani, Dena Cohen, Andy Rawstron, Christopher F.E. Pocock, Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study Blood. ,vol. 116, pp. 697- 697 ,(2010) , 10.1182/BLOOD.V116.21.697.697
Marek Kasznicki, Anna Dmoszyńska, Jerzy Z. Bloński, Barbara Zdziarska, Pawel Grieb, Stanislaw Potoczek, Aleksander B. Skotnicki, Wieslaw Nowak, Tadeusz Robak, Andrzej Hellmann, Lech Konopka, Bernadeta Ceglarek, Maria Blasińska-Morawiec, Euzebiusz Krykowski, Sabina Kotlarek-Haus, Halina Mrugala-Śpiewak, Stanislaw Maj, Jadwiga Dwilewicz-Trojaczek, Ignacy Urasiński, Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood. ,vol. 96, pp. 2723- 2729 ,(2000) , 10.1182/BLOOD.V96.8.2723.H8002723_2723_2729
Valentin Goede, Kirsten Fischer, Kathryn Humphrey, Elina Asikanius, Raymonde Busch, Anja Engelke, Clemens M. Wendtner, Olga Samoylova, Tatiana Chagorova, Marie-Sarah Dilhuydy, Javier De La Serna Torroba, Thomas Illmer, Stephen Opat, Carolyn Owen, Karl A Kreuzer, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Michael Wenger, Michael Hallek, Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. Journal of Clinical Oncology. ,vol. 31, pp. 7004- 7004 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.7004
A Osterborg, M J Dyer, D Bunjes, G A Pangalis, Y Bastion, D Catovsky, H Mellstedt, Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. ,vol. 15, pp. 1567- 1574 ,(1997) , 10.1200/JCO.1997.15.4.1567
Michael Steurer, Georg Pall, Sue Richards, Guido Schwarzer, Julia Bohlius, Richard Greil, Purine Antagonists for Chronic Lymphocytic Leukaemia Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD004270.PUB2
Susan M. O’Brien, Hagop Kantarjian, Deborah A. Thomas, Francis J. Giles, Emil J. Freireich, Jorge Cortes, Susan Lerner, Michael J. Keating, Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia Journal of Clinical Oncology. ,vol. 19, pp. 2165- 2170 ,(2001) , 10.1200/JCO.2001.19.8.2165
Paula Cramer, Michael Hallek, Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nature Reviews Clinical Oncology. ,vol. 8, pp. 38- 47 ,(2011) , 10.1038/NRCLINONC.2010.167
Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood. ,vol. 115, pp. 2578- 2585 ,(2010) , 10.1182/BLOOD-2009-08-236471
Xose S Puente, Magda Pinyol, Víctor Quesada, Laura Conde, Gonzalo R Ordóñez, Neus Villamor, Georgia Escaramis, Pedro Jares, Sílvia Beà, Marcos González-Díaz, Laia Bassaganyas, Tycho Baumann, Manel Juan, Mónica López-Guerra, Dolors Colomer, José MC Tubío, Cristina López, Alba Navarro, Cristian Tornador, Marta Aymerich, María Rozman, Jesús M Hernández, Diana A Puente, José MP Freije, Gloria Velasco, Ana Gutiérrez-Fernández, Dolors Costa, Anna Carrió, Sara Guijarro, Anna Enjuanes, Lluís Hernández, Jordi Yagüe, Pilar Nicolás, Carlos M Romeo-Casabona, Heinz Himmelbauer, Ester Castillo, Juliane C Dohm, Silvia de Sanjosé, Miguel A Piris, Enrique De Alava, Jesús San Miguel, Romina Royo, Josep L Gelpí, David Torrents, Modesto Orozco, David G Pisano, Alfonso Valencia, Roderic Guigó, Mónica Bayés, Simon Heath, Marta Gut, Peter Klatt, John Marshall, Keiran Raine, Lucy A Stebbings, P Andrew Futreal, Michael R Stratton, Peter J Campbell, Ivo Gut, Armando López-Guillermo, Xavier Estivill, Emili Montserrat, Carlos López-Otín, Elías Campo, None, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature. ,vol. 475, pp. 101- 105 ,(2011) , 10.1038/NATURE10113
J R Brown, J Abramson, E Hochberg, E Mikler, V Dalton, L Werner, H Reynolds, C Thompson, S M McDonough, Y Kuang, J Ritz, D Neuberg, A S Freedman, A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. ,vol. 24, pp. 1972- 1975 ,(2010) , 10.1038/LEU.2010.199